| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/07/2005 | US20050074797 FHIT proteins and nucleic acids and methods based thereon |
| 04/07/2005 | US20050074775 assessing GST-pi expression levels in fixed or fixed and paraffin embedded tissues using primers; pharmacogenetics; determining antitumor platinum-based chemotherapeutic regimen |
| 04/07/2005 | US20050074761 Novel means for the diagnosis and therapy of ctcl |
| 04/07/2005 | US20050074758 Prokineticin polypeptides, related compositions and methods |
| 04/07/2005 | US20050074757 Compositions and methods for inhibiting expression of a mutant gene |
| 04/07/2005 | US20050074755 Nucleotide sequences coding mutator locus gene for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074509 Inhibiting cell growth and/or killing tumor cells |
| 04/07/2005 | US20050074507 Polyherbal formulation for hepatic and splenic disorders |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074463 Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes |
| 04/07/2005 | US20050074457 Simplified, high throughput screening for identification of heat shock protein 90 ligands selective for high affinity form |
| 04/07/2005 | US20050074441 probiotics having immunomodulatory activity, used for prophylaxis gastrointestinal disorders such as inflammatory bowel disease or irritable bowel syndrome |
| 04/07/2005 | US20050074426 A conjugate of a cytokine and a tumor targeting moiety with numerous provisos |
| 04/07/2005 | US20050074401 Selective targeting of tumor vasculature using radiolabelled antibody molecules |
| 04/07/2005 | CA2814269A1 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 04/07/2005 | CA2540827A1 Methods of [11c]-radiolabelling phenothiazine and phenothiazine-like compounds |
| 04/07/2005 | CA2540701A1 Proteins expressed in nk cells |
| 04/07/2005 | CA2540364A1 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 04/07/2005 | CA2540104A1 Water soluble nanoparticles comprising inclusion complexes |
| 04/07/2005 | CA2540019A1 Quinazoline derivatives as antiproliferative agents |
| 04/07/2005 | CA2540008A1 Quinazoline derivatives |
| 04/07/2005 | CA2539727A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 04/07/2005 | CA2539694A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 04/07/2005 | CA2539534A1 Hippophae rhamnoides compositions for cancer therapy |
| 04/07/2005 | CA2539252A1 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents |
| 04/07/2005 | CA2539235A1 5-arylpyrimidines as anticancer agents |
| 04/07/2005 | CA2539117A1 Inhibitors of histone deacetylase |
| 04/07/2005 | CA2537876A1 Antibodies to m-csf |
| 04/07/2005 | CA2537520A1 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents |
| 04/06/2005 | EP1520856A1 Androgen receptor agonist |
| 04/06/2005 | EP1520855A1 Thieno(2,3-b)pyridine derivatives useful as antagonists of gonadotropin releasing hormone |
| 04/06/2005 | EP1520585A1 Cancer treatment using natural plant products or essential oils or components from some pistacia species |
| 04/06/2005 | EP1520579A1 Compositions for the treatment and prevention of cancer |
| 04/06/2005 | EP1520175A2 Oncolytic viruses as phenotyping agents for neoplasms |
| 04/06/2005 | EP1520032A2 Lung cancer therapeutics and diagnostics |
| 04/06/2005 | EP1520021A2 Antisense modulation of lrh1 expression |
| 04/06/2005 | EP1520015A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/06/2005 | EP1519961A1 Low molecular weight oversulfated polysaccharide |
| 04/06/2005 | EP1519960A2 Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof |
| 04/06/2005 | EP1519956A2 Epha2 monoclonal antibodies and methods of use thereof |
| 04/06/2005 | EP1519932A1 Bisarylsulfonamide compounds and their use in cancer therapy |
| 04/06/2005 | EP1519922A1 Di-aryl-substituted ethane pyridone pde4 inhibitors |
| 04/06/2005 | EP1519921A2 Substituted anthranilic amide derivatives and methods of use |
| 04/06/2005 | EP1519915A2 Tricyclic steroid hormone nuclear receptor modulators |
| 04/06/2005 | EP1519908A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 04/06/2005 | EP1519757A1 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 04/06/2005 | EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 04/06/2005 | EP1519749A1 Chemotactic factor inhibitor for modulating inflammatory reactions |
| 04/06/2005 | EP1519747A2 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 04/06/2005 | EP1519735A2 Assays and implements for determining and modulating hsp90 binding activity |
| 04/06/2005 | EP1519733A1 Compositions for cancer therapy comprising saponins or sapogenins |
| 04/06/2005 | EP1519730A1 Novel use of imidazotriazinones |
| 04/06/2005 | EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 04/06/2005 | EP1519724A1 Fredericamycin derivatives as medicaments for treating tumours |
| 04/06/2005 | EP1519718A1 At least partially degradable films containing an active ingredient and method for the production thereof |
| 04/06/2005 | EP1519683A2 Solid hydrogel coupling for ultrasound imaging and therapy |
| 04/06/2005 | EP1414817B1 substituted isoindoles and the use thereof |
| 04/06/2005 | EP1307455B1 Inhibitors of alpha-l beta-2 mediated cell adhesion |
| 04/06/2005 | EP1284997B1 Therapeutic compounds for ovarian cancer |
| 04/06/2005 | EP1218494B1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 04/06/2005 | EP1218357B1 Quinazoline derivatives |
| 04/06/2005 | EP1162993B1 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 04/06/2005 | EP1113809B1 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 04/06/2005 | EP1090012A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP1090011A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP0984930B1 2-indolinone derivatives as modulators of protein kinase activity |
| 04/06/2005 | EP0912521B1 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| 04/06/2005 | EP0748219B1 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/06/2005 | CN1604968A Methods to treat diabetes and related conditions based on polymorphisms in the TCF-1 gene |
| 04/06/2005 | CN1604966A Direct targeting binding proteins |
| 04/06/2005 | CN1604965A 生长激素融合蛋白 Growth hormone fusion protein |
| 04/06/2005 | CN1604963A Method for the in vitro synthesis of short double stranded RNAs |
| 04/06/2005 | CN1604910A Affinity enhancement agents |
| 04/06/2005 | CN1604901A Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/06/2005 | CN1604900A 6-aminomorphinane derivatives, method for production and use thereof |
| 04/06/2005 | CN1604898A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds |
| 04/06/2005 | CN1604890A 取代的环己烷衍生物 Substituted cyclohexane derivatives |
| 04/06/2005 | CN1604795A Combination motif immune stimulatory oligonucleotides with improved activity |
| 04/06/2005 | CN1604788A High-concentration protein formulations and method of manufacture |
| 04/06/2005 | CN1604783A Drug for treating a fibrotic disease through rna interfence |
| 04/06/2005 | CN1604778A Cis-imidazolines |
| 04/06/2005 | CN1604774A 血管生成抑制剂 An angiogenesis inhibitor |
| 04/06/2005 | CN1604772A Transdermal transport of compounds |
| 04/06/2005 | CN1603404A Oncolytic adenovirus with target for liver cancer and its preparation method and use |
| 04/06/2005 | CN1603345A Trivalent bispecific antibody and its preparation process and use |
| 04/06/2005 | CN1603341A Human calcium ion / calmodulin deopendent protein kinase II inhibitory protein alpha, its coded sequence and use |
| 04/06/2005 | CN1603340A Antitumor activity of squash protein and use thereof |
| 04/06/2005 | CN1603314A Pyrazolobenzodiazepines as CDK2 inhibitors |
| 04/06/2005 | CN1603307A Cyanoacrylate derivatives and their preparation method and biological activity |
| 04/06/2005 | CN1602956A Deactivated BCG for treating disease |
| 04/06/2005 | CN1602952A Tumor cell apoptosis accelerating medicine |
| 04/06/2005 | CN1602938A Leukemia treating pills |
| 04/06/2005 | CN1602920A Gingko leaf extracts with superior quality and its manufacturing technique |
| 04/06/2005 | CN1602914A Tumor eliminating powder |
| 04/06/2005 | CN1602854A Taxel preparation for intravenous injection |
| 04/06/2005 | CN1602844A Mitoxantrone or mitoxantrone hydrochloride liposome injection and its preparing process |
| 04/06/2005 | CN1195860C Delivery of biologically active polypeptides |
| 04/06/2005 | CN1195859C Modified human granulocyte-colony stimulating factor and process for producing same |
| 04/06/2005 | CN1195849C APPIL-a novel protein with growth effects |